Would you consider TKI discontinuation in a patient who has negative BCR transcripts on Bosutinib?  

Yes, I would certainly consider it provided they meet the criteria. Those criteria would be no different than for the other TKI. It is generally considered that the expectations are the same for all TKIs (with more patients eligible with second generation TKI than with imatinib). Most of this is ext...